Abstract
Panitumumab is the first fully human anti-EGFR monoclonal antibody available for the treatment of advanced colorectal cancer. The drug appears to be well tolerated and has demonstrated antitumor activity and clinical benefit both as a single agent and in combination with cytotoxic chemotherapy.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 10-14+16 |
| Journal | Community Oncology |
| Volume | 3 |
| Issue number | 10 SUPPL. 4 |
| State | Published - Oct 1 2006 |
ASJC Scopus subject areas
- Hematology
- Oncology